Company Overview of Power 3 Medical Products Inc.
Power3 Medical Products, Inc., a bio-technology company, focuses on the development of diagnostic tests in the fields of cancer, and neurodegenerative, and neuromuscular diseases in the United States. The company develops a portfolio of products, including BC-SeraPro, a blood serum test for the early detection of breast cancer; and NuroPro, a blood serum test for the detection of neurodegenerative diseases, such as amytrophic lateral sclerosis, Alzheimer’s, and Parkinson’s diseases. Its products are designed to analyze proteins and their mutations to assess an individual’s risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient...
26022 Budde Road
The Woodlands, TX 77380
Founded in 1992
Key Executives for Power 3 Medical Products Inc.
Chief Executive Officer, Interim Chief Financial Officer, Chief Accounting Officer and Director
Interim Chairman, President, Chief Scientific Officer, Director of Proteomics, Secretary and Member of Scientific Advisory Board
Director of Laboratory Operations
Compensation as of Fiscal Year 2014.
Power 3 Medical Products Inc. Key Developments
SEC Revokes Registration Of Registered Securities Of Power 3 Medical Products
Oct 10 14
An Administrative Law Judge has issued an Initial Decision of Default as to Power 3 Medical Products Inc. The Initial Decision found that the company was issuer of securities registered pursuant to Section 12(g) of the Securities Exchange Act of 1934 (Exchange Act), and the company failed to comply with Section 13(a) of the Exchange Act and Exchange Act Rules 13a-1 and/or 13a-13 by not filing required periodic reports with the Securities and Exchange Commission (SEC). The Initial Decision finds these allegations to be true and revokes the registration of each class of the company’s registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.
SEC Orders Hearings On Registration Suspension Or Revocation Against Power 3 Medical Products Inc. For Failure To Make Required Periodic Filings
Sep 15 14
Securities and Exchange Commission (SEC or the commission) instituted public administrative proceeding to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Power 3 Medical Products Inc. for failure to make required periodic filings with the Commission. In this Order, the Division of Enforcement (Division) alleges that the company was delinquent in its required periodic filings with the Commission. In this proceeding, instituted pursuant to Exchange Act Section 12(j), a hearing will be scheduled before an Administrative Law Judge. At the hearing, the judge will hear evidence from the Division and the company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceeding will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of the company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in this proceeding issue an initial decision not later than 120 days from the date of service of the order instituting proceeding.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries